Evolus raises 2026 revenue guidance, adds Profhilo to U.S. pipeline via IBSA deal
The aesthetics company posted 21% revenue growth for the second quarter, expanded its injectable portfolio with new licensing deals, and reaffirmed 2028 targets.
Evolus, Inc. reported second quarter 2026 financial results on August 5, 2026, showing total net revenues of $84.1 million, a 21% increase over the second quarter of 2025.1 The company said this marked its third consecutive quarter of positive Adjusted EBITDA1, which came in at $4.7 million in the second quarter of 2026, compared to a loss of $7.9 million in the second quarter of 2025.1
On the pipeline, Evolus entered into an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo in the United States1, describing it in the release headline as the third vertical in the U.S. injectable portfolio, with estimated peak annual revenue exceeding $100 million and anticipated U.S. commercialization in 2030.1 The company also expanded its exclusive licensing agreement with Symatese to include Canada, Australia, and New Zealand1, with expected commercialization in 2028.1
On its other HA candidate, Evolus said it continued advancing Evolysse Sculpt through the FDA review process and remains focused on bringing the product to market.1 In its full-year guidance, the company listed the anticipated U.S. approval of Evolysse Sculpt in the fourth quarter of 2026; however, guidance assumes no revenue contribution from the product.1 That caveat leaves open whether approval will occur on that timeline or generate sales this year.
Evolus raised full-year 2026 revenue guidance to between $330 million and $337 million, raised adjusted gross profit margin guidance to between 67.0% and 67.5%, and narrowed non-GAAP operating expense guidance to between $212 million and $216 million.1 It also reaffirmed its 2028 long-term outlook of $450 million to $500 million in net revenue, a three-year CAGR of 15% to 19%, and Adjusted EBITDA margins of 13% to 15%.1
On cash, the company reported $45.2 million in cash and cash equivalents as of June 30, 2026, compared to $49.8 million on March 31, 20261, and said it expects to maintain approximately $120 million of additional non-dilutive capacity, providing sufficient resources to execute the Company's strategic priorities.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.